Video Series

Clascoterone cream 1% plus adapalene gel 0.3% offers an effective, well-tolerated topical option for moderate to severe acne, with combination therapy enhancing adherence and outcomes.

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of Nefecon in patient care.

Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.

Standardized monitoring workflows and clearer reimbursement support are critical to improving community clinicians’ readiness to deliver bispecific antibodies safely in the outpatient setting.

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.

Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in relapsed/refractory multiple myeloma, while raising important questions about how best to sequence bispecific combinations with CAR T-cell therapy.

While earlier-line BCMA CAR T-cell therapy in multiple myeloma offers superior efficacy and longer treatment-free survival, careful monitoring and further research are needed to manage rare but serious toxicities.

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and stronger multidisciplinary collaboration can significantly improve clinician confidence and real-world uptake.

Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for those with HER2 mutations.

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of Nefecon in patient care.

Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors.

Steven Stoner, PharmD, advises managed care teams to use rigorous diagnostic assessments, monitor adherence, and invest heavily in early patient follow-up to accurately attribute costs to treatment-resistant depression.

Explore the latest findings from the KATHERINE, PATINA, and HER2CLIMB-05 trials, highlighting advancements and challenges in breast cancer treatment.

Steven Stoner, PharmD, advocates for integrating patient-reported outcomes and digital monitoring to identify early treatment failure and justify utilizing highly effective therapies like dextromethorphan-bupropion sooner.

Explore the unique mechanisms of bispecific antibodies and their rapid availability compared to CAR T-cell therapies in cancer treatment.

Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications.

Panelists discuss how emerging therapies targeting new pathways may revolutionize schizophrenia management.

Panelists discuss how optimizing safety and cost-efficiency are central to improving adherence and overall health care value.

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and treatment access.

Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients.

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with longer PFS, suggesting T-cell composition may serve as a biomarker to guide patient selection.

Michael Wang, MD, reviews ASH 2025 data showing durable safety with long-term BTK inhibition, promising next-generation targeted agents, sustained CAR T-cell efficacy, and evidence favoring upfront combination therapy over sequential treatment in mantle cell lymphoma.

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with operational efficiency and cost savings serving as added benefits rather than decision drivers.

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T feasibility, expansion, and durability compared with later-line treatment.

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency and generate cost savings for oncology practices without affecting efficacy or safety.

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK inhibitor–refractory disease.

Explore the latest findings from the KATHERINE, PATINA, and HER2CLIMB-05 trials, highlighting advancements and challenges in breast cancer treatment.